A Yeast/Drosophila Screen to Identify New Compounds Overcoming Frataxin Deficiency

Figure 5

Drugs ability to rescue in vivo phenotypes induced by frataxin inactivation in Drosophila. (a) The timing of pupariation of da-GAL4>+ (+) and da-GAL4>UAS-fhRNAi (fhRNAi) larvae untreated (DMSO controls) or treated with compounds was followed. Percentages of larvae reaching pupariation 263 hours after egg laying (AEL) are shown. The 12 compounds selected in yeast were tested at 10 μM (grey bars) and 50 μM (black bars). Each treatment condition was tested on 3 to 4 samples of 50 larvae. All values are means (±SEM). Significant differences of da-GAL4>UAS-fhRNAi treated with a compound compared to untreated larvae of the same genotype are indicated: ^∗ and ^∗∗. (b) Percentages of larvae reaching pupariation as a function of time after egg laying for control larvae (+ DMSO) and frataxin depleted larvae and untreated (fhRNAi DMSO) and treated with 10 μM deferoxamine mesylate or LPS 01-04-L-G10 are shown. (c) Diastolic diameters of 4-day-old UAS-mitoGFP;HandGS>+ control () and UAS-mitoGFP;HandGS>UAS-fhRNAi adult male flies untreated () or treated during development with 10 μM LPS 01-04-L-G10 () or deferoxamine mesylate (). All values are means (±SEM). Significant differences between treated and untreated UAS-mitoGFP;HandGS>UAS-fhRNAi flies are indicated: ^∗ and ^∗∗.

(a)

(b)

(c)